Trials / Completed
CompletedNCT02946554
Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF
Multicenter Phase II Safety and Preliminary Efficacy Study of 2 Dose Regimens of HepaStem in Patients With Acute on Chronic Liver Failure
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Cellaion SA · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study will assess the safety of different dose regimens of HepaStem in cirrhotic Patients with ACLF or with acute decompensation at risk of developing ACLF up to Day 28 of the active study period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HepaStem |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2019-07-01
- Completion
- 2020-07-01
- First posted
- 2016-10-27
- Last updated
- 2020-10-14
Locations
10 sites across 2 countries: Belgium, France
Source: ClinicalTrials.gov record NCT02946554. Inclusion in this directory is not an endorsement.